The use of immunosuppression in autoimmune hepatitis: A current literature review by Angela Cropley, Martin Weltman

Get full text

Comparison between PSMA PET/CT and MRI for Characterizing <i>Hepatocellular carcinoma</i>: A Real-World Study by Veronica Chi Ken Wong, Joshua Yip, Vincenzo Fragomeli, Martin Weltman, Han Loh, Ken Le, Diep Nguyen, Chuong Bui, Robert Mansberg

Get full text

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial by Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, Alex M. DePaoli

Get full text

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial by Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, the DARLO‐C Study Group

Get full text

A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes by Jawaher Alharthi, Ali Bayoumi, Khaled Thabet, Ziyan Pan, Brian S. Gloss, Olivier Latchoumanin, Mischa Lundberg, Natalie A. Twine, Duncan McLeod, Shafi Alenizi, Leon A. Adams, Martin Weltman, Thomas Berg, Christopher Liddle, Jacob George, Mohammed Eslam

Get full text

Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma by Jason Behary, Nadia Amorim, Xiao-Tao Jiang, Anita Raposo, Lan Gong, Emily McGovern, Ragy Ibrahim, Francis Chu, Carlie Stephens, Hazem Jebeili, Vincenzo Fragomeli, Yen Chin Koay, Miriam Jackson, John O’Sullivan, Martin Weltman, Geoffrey McCaughan, Emad El-Omar, Amany Zekry

Get full text

Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up by Paul J. Clark, Patricia C. Valery, James Ward, Simone I. Strasser, Martin Weltman, Alexander Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, Peter Angus, Jacob George, Steven Bollipo, Bruce McGarity, William Sievert, Gerry Macquillan, Edmund Tse, Amanda Nicoll, Amanda Wade, Geoff Chu, Damian Harding, Wendy Cheng, Geoff Farrell, Stuart K. Roberts

Get full text

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study by Evan B. Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S. Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely, on behalf of the ACTIVATE Study Group

Get full text

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study by Haiyan Ma, Tien Huey Lim, Apinya Leerapun, Martin Weltman, Jidong Jia, Young-suk Lim, Pisit Tangkijvanich, Wattana Sukeepaisarnjaroen, Yun Ji, Nina Le Bert, Dong Li, Yao Zhang, Robert Hamatake, Nicole Tan, Chunming Li, Simone I. Strasser, Huiguo Ding, Jung-Hwan Yoon, Nigel H. Stace, Tanvir Ahmed, Dave E. Anderson, Li Yan, Antonio Bertoletti, Qing Zhu, Man-Fung Yuen

Get full text

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C by Khaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, Manuel Romero-Gomez, Alessandra Mangia, William L. Irving, Thomas Berg, Gregory J. Dore, Henning Grønbæk, David Sheridan, Maria Lorena Abate, Elisabetta Bugianesi, Martin Weltman, Lindsay Mollison, Wendy Cheng, Stephen Riordan, Janett Fischer, Ulrich Spengler, Jacob Nattermann, Ahmed Wahid, Angela Rojas, Rose White, Mark W. Douglas, Duncan McLeod, Elizabeth Powell, Christopher Liddle, David van der Poorten, Jacob George, Mohammed Eslam, International Liver Disease Genetics Consortium

Get full text

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. by Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, Kate S O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J Dore, William L Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Müller, Emma Hammond, David Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J Stewart, Jacob George, David R Booth, International Hepatitis C Genetics Consortium (IHCGC)

Get full text

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC) by Alan Wigg, Jonathan Tibballs, Richard Woodman, Katherine Stuart, Hien Le, Stuart K. Roberts, John K. Olynyk, Simone I. Strasser, Michael Wallace, Jarad Martin, Annette Haworth, Nicholas Hardcastle, Kee Fong Loo, Colin Tang, Yoo Young Lee, Julie Chu, Richard De Abreu Lourenco, Adam Koukourou, Diederick De Boo, Kate McLean, Jackie Buck, Rohit Sawhney, Amanda Nicoll, Anouk Dev, Marnie Wood, Alicia Braund, Martin Weltman, Richard Khor, Miriam Levy, Tim Wang, Michael Potter, James Haridy, Ashok Raj, Oliver Duncan, Amany Zekry, Natalie Collier, James O’Beirne, Catherine Holliday, Yuvnik Trada, Jaw Tronidjaja, Jacob George, David Pryor

Get full text